Navigation Links
Cumberland Pharmaceuticals Announces Appointments

NASHVILLE, Tenn., Dec. 18 /PRNewswire/ -- Cumberland Pharmaceuticals is pleased to announce the appointment of two senior executives.

David L. Lowrance has been promoted to Vice President and Chief Financial Officer. In this role, he is responsible for overseeing the company's accounting and financial activities, including financial reporting and planning. Mr. Lowrance has 17 years of financial and accounting experience, joining Cumberland in 2003 as Director of Finance and Accounting. He spent eight years with two global conglomerates, including four years as senior vice president for Icore International. Prior to this, Mr. Lowrance spent four years at Ernst & Young, LLP. A graduate of the University of Georgia, he is a certified public accountant.

Doug Jack has joined the company as Senior Manager of SEC Reporting. He is responsible for the preparation of all SEC-required financial reports. Mr. Jack brings more than 14 years of accounting and financial experience to his position. Prior to joining Cumberland, he spent eight years as audit manager with Ernst & Young and PricewaterhouseCoopers, and served as CFO and controller at Southern Specialty Brands. A certified public accountant, he is a graduate of the University of Georgia.

"We are fortunate to work with these outstanding individuals who bring great depth of experience and knowledge in their respective areas," said A.J. Kazimi, Cumberland's Chief Executive Officer. "Each will play an important role in taking the company to the next level as we continue to grow and capitalize on opportunities created by the shifting pharmaceutical landscape."

About Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. Cumberland's primary target markets include hospital acute care and gastroenterology. Cumberland markets Acetadote(R) for the treatment of acetaminophen poisoning and Kristalose(R), a prescription strength laxative. The Company is also developing Amelior(R) which is in Phase III studies for the treatment of both pain and fever. Cumberland is dedicated to providing innovative products which improve quality of care for patients.

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Orion ICG, LLC Announces Acquisition of Cumberland Therapy Services, Inc.
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... payment industry today announced its strategic partnership with Connance, a healthcare industry ... The two companies’ proven, proprietary technology combine to provide health systems, hospitals ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, ... editors can give their videos a whole new perspective by using the title ... Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to choose ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
(Date:6/23/2016)... June 23, 2016 Bracket , a leading ... next generation clinical outcomes platform, Bracket eCOA (SM) 6.0, ... June 26 – 30, 2016 in Philadelphia ... Clinical Outcome Assessment product of its kind to fully integrate ... Bracket eCOA 6.0 is a flexible platform for electronic ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia ... the company,s second affiliate in Latin America . ... ... Farma Colombia ... ...
Breaking Medicine Technology: